Digital Utilities Ventures Reports Strong Fiscal Year 2024 - Advancing Leadership in Green Technologies
September 23, 2024 09:00 ET
|
Digital Utilities Ventures, Inc.
Digital Utilities Ventures Reports Strong Fiscal Year 2024 - Advancing Leadership in Green Technologies
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement
September 23, 2024 08:00 ET
|
European Microbiome Innovation for Health
European Microbiome Innovation for Health and Microbiome Therapeutics Innovation Group Announce New Collaboration Agreement Paris, France, September 23, 2024, 2:00 pm CET - The European Microbiome...
Pharmagreen Biotech, Inc. (PHBI) Reaffirms Commitment to Non-Toxic Financing Amid Ongoing Business Development Progress
September 19, 2024 07:30 ET
|
Pharmagreen Biotech, Inc.
CARSON CITY, NV, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is pleased to announce the continued advancement of its business...
Fairway Consulting Group Appoints Brennan Clark as Vice President of Executive Search
September 17, 2024 13:25 ET
|
Fairway Consulting Group
Fairway Consulting Group (FCG) appoints Brennan Clark as Vice President of Executive Search.
Elicio Therapeutics Reports Inducement Grants
September 17, 2024 08:31 ET
|
Elicio Therapeutics Inc.
BOSTON, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
September 17, 2024 06:30 ET
|
ANEW MEDICAL, INC.
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc.
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
September 16, 2024 06:30 ET
|
Cybrexa Therapeutics
Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors
Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)
September 16, 2024 04:00 ET
|
Certa Therapeutics
MELBOURNE, Australia, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Certa Therapeutics (Certa), a biotechnology company developing innovative precision therapies for patients with fibrotic diseases, today...
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
September 15, 2024 03:00 ET
|
23andMe, Inc.
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and tumor-bound ULBP6 confirmed in squamous cell carcinomas and...
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
September 15, 2024 03:00 ET
|
23andMe, Inc.
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression of CD200 and human...